© 2021 MJH Life Sciences and Drug Topics. All rights reserved.
© 2021 MJH Life Sciences™ and Drug Topics. All rights reserved.
Joseph E. Cruz, Pharm.D., BCPS is Clinical Assistant Professor at Rutgers University, and The State University of New Jersey Clinical Coordinator - Internal Medicine Englewood Hospital and Medical Center.
March 15, 2017
Cangrealor is the first FDA-approved P2Y12 inhibitor.
January 26, 2017
The first of their kind, evolocumab and alirocumab belong to a new class of cholesterol lowering agents.
December 15, 2016
Entresto® is a newly approved combination of sacubitril, a neprilysin inhibitor, and valsartan, an angiotensin II receptor blocker (ARB) for patients who have chronic heart failure NYHA Class II-IV and reduced ejection fraction.